Fox Run Management’s Axsome Therapeutics AXSM Stock Holding History

Fox Run Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$810K	Buy	+3,308	New	+$717K	0.13%	263
2025 Q2	–	Sell	-13,584	Closed	-$1.58M	–	865
2025 Q1	$1.58M	Buy	13,584 +7,465	+122%	+$850K	0.25%	69
2024 Q4	$518K	Buy	+6,119	New	+$563K	0.09%	427
2023 Q4	–	Sell	-5,250	Closed	-$367K	–	731
2023 Q3	$367K	Buy	+5,250	New	+$392K	0.11%	365
2023 Q1	–	Sell	-3,416	Closed	-$263K	–	653
2022 Q4	$263K	Sell	3,416 -2,451	-42%	-$147K	0.11%	389
2022 Q3	$262K	Buy	+5,867	New	+$293K	0.1%	396
2021 Q2	–	Sell	-3,797	Closed	-$215K	–	341
2021 Q1	$215K	Buy	+3,797	New	+$267K	0.39%	158

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fox Run Management's AXSM Position: Q2 2026 in Review

Fox Run Management opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 3,308 shares worth $810K. The stake represents 0.13% of the portfolio and ranks #263 among its holdings. This is a return to the name: Fox Run Management previously reported a position in AXSM as recently as Q1 2025.

Fox Run Management first reported a position in AXSM in Q1 2021 and has held it in 7 quarters since. The position peaked at $1.58M in Q1 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Fox Run Management held 3,308 shares of Axsome Therapeutics worth $810K as of Q2 2026.
Axsome Therapeutics was a new Fox Run Management position in Q2 2026.
Axsome Therapeutics made up 0.13% of Fox Run Management's portfolio in Q2 2026, its #263 holding.
Fox Run Management first reported a position in Axsome Therapeutics in Q1 2021 and has held it in 7 quarters since.
Fox Run Management's Axsome Therapeutics position peaked at $1.58M in Q1 2025.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.